FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) > Single Chain Antibody

Single Chain Antibody

Single Chain Antibody patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/21/14 - 20140234312 - Inhibition of tumor metastasis
The invention provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis....

08/21/14 - 20140234313 - Soluble polypeptides
The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired VL and VH domains that demonstrate soluble expression and folding in a reducing or intracellular environment. The invention also relates to polynucleotides encoding such polypeptides,...

08/21/14 - 20140234314 - Antibodies against epidermal growth factor receptor (egfr) and uses thereof
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed....

08/21/14 - 20140234315 - Scfv antibodies which pass epithelial and/or endothelial layers
scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said...

08/21/14 - 20140234316 - Vaccibodies targeted to cross-presenting dendritic cells
The present invention relates to recombinant fusion proteins targeted to dendritic cells and uses thereof. In particular, the present invention relates to fusion proteins comprising an antibody component and a targeting components, and uses of such fusion proteins to trigger immune responses....

08/14/14 - 20140227270 - Bispecific anti-cxcr7 immunoglobulin single variable domains
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present...

08/14/14 - 20140227271 - Somatic mutations in atrx in brain cancer
We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that...

08/14/14 - 20140227272 - Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a...

08/14/14 - 20140227273 - Multi-specific binding molecules targeting aberrant cells
Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in...

08/07/14 - 20140220018 - Biomarkers for epithelial cancer diagnosis and treatment
Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject. Also disclosed are methods of determining prognosis of a subject with an epithelial tumor. These methods include, in...

07/31/14 - 20140212421 - Methods and compositions for enhanced delivery of macromolecules
The invention provides compositions and methods that enhance the delivery of large macromolecules (i.e., greater than 10 kDa), such as antigen-binding polypeptides, across tight junctions. Such methods and compositions are particularly useful for delivering therapeutic antigen-binding polypeptides to the CNS, via intranasal administration, for the treatment of neurological disorders....

07/31/14 - 20140212422 - Methods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions...

07/24/14 - 20140205601 - Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid...

07/24/14 - 20140205602 - Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof...

07/24/14 - 20140205603 - Siglec-15 antibodies in treating bone loss-related disease
Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell...

07/24/14 - 20140205604 - Antigen binding constructs
The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising...

07/17/14 - 20140199306 - Compositions and methods for antibodies targeting epo
The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling....

07/17/14 - 20140199307 - Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about...

07/17/14 - 20140199308 - Compositions and methods to enhance the immune system
The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune...

07/17/14 - 20140199309 - Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors
The invention provides methods for treating HIF-1α-overexpressing human tumors, inhibiting HIF-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90α from the tumors....

07/17/14 - 20140199310 - Compositions comprising agents that inhibit neuropilin and tolloid like 2
We disclose agents that inhibit the expression of NETO-2 which has elevated expression in cancer stem cells; the use of NETO-2 as a diagnostic or prognostic marker of tumour initiation; the use NETO-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind NETO-2 and vaccines...

07/17/14 - 20140199311 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the...

07/10/14 - 20140193412 - Treatment of cutaneous wounds by inhibiting cold shock proteins
Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor....

07/10/14 - 20140193413 - Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs)...

07/03/14 - 20140186352 - Anti-granulysin antibodies and methods of use thereof
An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or...

07/03/14 - 20140186353 - Treatment of inflammatory diseases by inhibiting cold-inducible rna-binding protein (cirp)
Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein....

06/26/14 - 20140178382 - Antibodies against monocyte chemotactic proteins
The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same....

06/26/14 - 20140178383 - Stable formulations of polypeptides and uses thereof
The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention....

06/26/14 - 20140178384 - Post-translationally modified neurotrophins
The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to...

06/26/14 - 20140178385 - Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14....

06/26/14 - 20140178386 - Functionalized polypeptides
The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in...

06/26/14 - 20140178387 - Antibody molecules having binding specificity for human il-13
The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules....

06/19/14 - 20140170143 - Use of an anti-cd200 antibody for prolonging the survival of allografts
The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200...

06/19/14 - 20140170144 - Antibody recognizing n-domain of midkine
The present disclosure relates to isolated or recombinant proteins, such as antibodies, which inhibit or reduce the function of midkine (hereinafter, referred to as “MK”) for use in the treatment or prevention of midkine-related disorders....

06/19/14 - 20140170145 - Compositions and methods of use for mgd-csf in disease treatment
Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are...

06/19/14 - 20140170146 - Methods for multiplexed drug evaluation
Methods for multiplexed delivery of agents to a solid tissue in vivo followed by assessment of efficacy with mass spectrometry are described....

06/19/14 - 20140170147 - Compositions and methods of use for antibodies of dickkopf-1
Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition....

06/05/14 - 20140154250 - Single-chain multivalent binding proteins with effector function
The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins....

06/05/14 - 20140154251 - Anti c-met antibody and uses thereof
An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided....

05/29/14 - 20140147442 - Use of il-23 antagonists for treatment of infection
Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections....

05/22/14 - 20140140997 - Methods of treating retroviral infections in felines
Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent...

05/08/14 - 20140127203 - Single-chain multivalent binding proteins effector function
Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as...

05/08/14 - 20140127204 - Anti-properdin antibodies
A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject....

05/08/14 - 20140127205 - Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions
The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3,...

05/08/14 - 20140127206 - Methods of treating pain using an il-31 monoclonal antibody
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated....

05/08/14 - 20140127207 - Antibodies against epidermal growth factor receptor (egfr) and uses thereof
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed....

05/08/14 - 20140127208 - Anti-complement c1s antibodies and uses thereof
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions....

05/01/14 - 20140120092 - Antigen binding proteins that bind erbb3
There is disclosed compositions and methods relating to or derived from anti-ErbB3 antibodies. More specifically, there is disclosed fully human antibodies that bind ErbB3, ErbB3-binding fragments and derivatives of such antibodies, and ErbB3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and...

05/01/14 - 20140120093 - Anti-infective binding proteins that bind aip2
There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and...

05/01/14 - 20140120094 - Use of il-20 antagonists for treating liver diseases
Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway....

04/24/14 - 20140112925 - Single chain antigen recognizing constructs (scarcs) stabilized by the introduction of novel disulfide bonds
The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized...